Patients

Delivering on our Commitment

At Avidity, we strive to incorporate patient and family voices into everything we do. We understand that living with a rare disease presents many challenges for patients and their families and we are committed to listening, learning, and partnering with the patient and advocacy community. Patient and caregiver perspectives inform our research and development, and inspire us as we stay committed to our mission to improve the lives of people affected by serious diseases. Our commitment to patients, especially patient safety, is our top priority at Avidity. If you are an advocate interested in helping us increase awareness of rare diseases, please send an email to Patients@aviditybio.com.

Russell’s Story

Loraine’s Story

Lee’s Story

Nathan’s Story

Karin’s Story

Amy’s Story

Luke’s Story

Community Communications

March 2024 – Del-desiran (AOC 1001) MARINA-OLE™ Long-term Data and Phase 3 HARBOR Study

December 2023 – AOC 1044 Healthy Volunteer Data Update

October 2023 – AOC 1001 Data Update

Clinical Studies

HARBOR™ will be a randomized, placebo-controlled, double blind Phase 3 clinical trial to evaluate del-desiran (AOC 1001) in people living with DM1. The HARBOR trial is set to begin in Q2 2024. Additional information will be added as the trial gets underway.

MARINA-OLE™ is an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of del-desiran in participants with DM1 who were previously enrolled in the MARINA^® Phase 1/2 trial. For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT05479981.

The EXPLORE44™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 skipping (DMD44). For more information on this study click here or visit www.clinicaltrials.gov and search for NCT05670730.

The FORTITUDE™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate single and multiple doses of AOC 1020 in approximately 70 adult participants with facioscapulohumeral muscular dystrophy (FSHD). For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT05747924.